TY  - CHAP
M1  - Book, Section
TI  - Overview of Clinical Bone Marrow Transplantation
A1  - Nikiforow, Sarah
A1  - Spitzer, Thomas R.
A2  - Chabner, Bruce A.
A2  - Longo, Dan L.
PY  - 2016
T2  - Harrison's Manual of Oncology, 2e
AB  - Bone  marrow  or  hematopoietic  cell  transplantation  (BMT  or  HCT)  is  a  potentially  curative  therapy  for  a  wide  variety  of  life-threatening  congenital  and  acquired  hematopoietic  stem  cell  disorders  and  neoplastic  diseases.  With  the  development  of  human  leukocyte  antigen  (HLA)  typing  to  identify  suitably  matched  donors,  advances  in  tolerability  and  efficacy  of  conditioning  regimens,  improvements  in  supportive  care,  and  advances  in  the  prophylaxis  and  treatment  of  graft-versus-host  disease  (GVHD),  clinical  HCT  became  a  reality.  Many  of  the  initial  clinical  HCT  efforts  were  directed  toward  severe  aplastic  anemia  and  acute  leukemia  (which  remains  the  paradigm  for  allogeneic  HCT  in  adults).  However,  the  demonstration  of  lasting  donor  lymphohematopoietic  reconstitution,  the  powerful  cytoreductive  effect  of  intensive  pretransplantation  conditioning  therapy,  and  the  exploitation  of  a  potent  immunologically-mediated  graft-versus-tumor  (GVT)  effect  led  to  the  successful  application  of  HCT  as  up-front  and  salvage  therapy  for  the  many  hematologic  malignancies  and  other  disorders  shown  in  Table  38-1.  Some  applications  of  HCT  are  potentially  curative,  e.g.,  allogeneic  transplantation  for  acute  myeloid  leukemia  (AML).  In  other  settings,  HCT  is  primarily  utilized  to  lengthen  disease-free  intervals  without  expectation  of  cure,  e.g.,  autologous  transplantation  for  multiple  myeloma.  In  parallel  with  the  above  advances,  the  use  of  hematopoietic  cell  transplantation  has  expanded  yearly.  In  2009,  more  than  26,000  transplants  were  performed  worldwide,  over  15,000  of  these  being  allogeneic  HCTs  (1).  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - hemonc.mhmedical.com/content.aspx?aid=1127648479
ER  -